B of A Securities Reiterates Rating on Avalo Therapeutics, Inc. $AVTX
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities reiterated its rating on Avalo Therapeutics, Inc. ($AVTX) to a "buy" rating in a recent research note and set a price target of $35, a 144.24% upside from the current price.
Avalo Therapeutics, Inc. Stock Down 26.9%
Shares of Avalo Therapeutics, Inc. ($AVTX) traded around $14.33 on Saturday, down 26.9% for the day.
Avalo Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Get Avalo Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AVTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.